Monoclonal antibodies are redefining therapeutic possibilities in animal health, offering precise, targeted alternatives to traditional treatments. With next-generation innovation expanding into new disease areas and species, changemakers at the forefront examine the opportunities and hurdles that will shape development, approval, and adoption.
- Regulatory pathways – navigating approval processes for novel biologics
 - Clinical adoption – driving veterinary education and confidence in new therapies
 
Speaker(s): 
Panellists

Denise Bevers
President & CEO
VETmAb Biosciences, Inc

Steve Nanchen
Senior Director, External Innovation EU & APAC Pacific
Elanco
Time: 
3:15pm - 3:45pm
Agenda Track No.: 
Track 5
Session Type: 
General Session (Presentation)